Compare GEL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | IOVA |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1996 | 2008 |
| Metric | GEL | IOVA |
|---|---|---|
| Price | $16.38 | $3.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $19.50 | $9.00 |
| AVG Volume (30 Days) | 278.9K | ★ 13.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,912,770,000.00 | N/A |
| Revenue This Year | $12.12 | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $14.55 | $1.67 |
| 52 Week High | $18.64 | $5.63 |
| Indicator | GEL | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 46.22 |
| Support Level | $16.28 | $3.23 |
| Resistance Level | $16.42 | $4.27 |
| Average True Range (ATR) | 0.47 | 0.26 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 47.03 | 20.11 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.